Nasdaq
$0.6208▲ 2.58%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $26.1MShares out 42.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 3d agoPre-market26.10.22 21:008-KKey event#●●●#●●●
MIRA PHARMACEUTICALS, INC.Bullish
MIRA Pharmaceuticals announced positive results from a 21-day preclinical study of MIRA-55 in a chronic inflammatory pain model. The drug demonstrated pain-relieving and anti-inflammatory effects comparable to Celebrex, and the company plans to submit an Investigational New Drug (IND) application in the first quarter of 2027.…more
$0.6208+2.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17Pre-market26.09.17 21:308-KKey event
MIRA PHARMACEUTICALS, INC.
MIRA Pharmaceuticals has submitted the Phase 2a clinical protocol for its CIPN treatment candidate, Ketamir-2, to the Institutional Review Board (IRB) following FDA review. The company is targeting site initiation in the first quarter of 2027, marking the first evaluation of the drug's efficacy and dose-response in patients.…more
$0.6208+2.58%vs prev closeView filingShare - 9.16After-hours26.09.17 05:308-KKey event
MIRA PHARMACEUTICALS, INC.
MIRA Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 11, 2026, where all three proposals, including the election of directors and the appointment of an independent auditor, were approved. As of the July 21, 2026 record date, there were 42,022,087 shares of common stock outstanding, with 26,499,076 shares (approximately 63.06%) represented at the meeting.…more
$0.6208+2.58%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:00#●●●#●●●
Mira Pharmaceuticals Reports Positive Preclinical Results for MIRA-55
Mira Pharmaceuticals announced that its oral pain therapeutic candidate MIRA-55 demonstrated significant pain relief comparable to Celebrex in a preclinical chronic inflammatory pain study. These results are based on animal models, and the company plans to continue development toward an IND submission.…more
$0.6208+2.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.17Pre-market26.09.17 21:30
●●●●●●●● ●●●●● ●●●●●●
MIRA Pharmaceuticals has submitted its Phase 2a clinical protocol for Ketamir-2, a treatment for chemotherapy-induced peripheral neuropathy, following FDA feedback. The company is targeting site initiation in the first quarter of 2027, though the drug remains in early-stage development.…more
$0.6208+2.58%vs prev close - 9.1Regular26.09.02 02:12
●●●●●●●● ●●●●● ●●●●●●
MIRA Pharmaceuticals shares surged following positive results from preclinical toxicology studies of its non-opioid pain drug candidate, MIRA-55. While these findings support the company's progress toward an IND application, the drug is still in the early stages of development.…more
$0.6208+2.58%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report